Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 14/20 | 0.73 |
| ▸ | MMP3 | P08254 | 5/20 | 0.59 |
| ▸ | MMP1 | P03956 | 4/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208045 | 1.00 | CPB2 (0.73) | CPB2MMP3MMP1MMP2CHRNB2 | |
| SCHEMBL3199733 | 0.85 | CPB2 (0.69) | CPB2MMP3MMP1CHRNB2CHRNB4 | |
| SCHEMBL3209744 | 0.85 | CPB2 (1.00) | CPB2 | |
| SCHEMBL3211133 | 0.83 | CPB2 (0.82) | CPB2 | |
| SCHEMBL3211162 | 0.83 | CPB2 (0.82) | CPB2 | |
| SCHEMBL27781388 | 0.82 | CPB2 (0.84) | CPB2 | |
| SCHEMBL3211782 | 0.82 | CPB2 (0.84) | CPB2 | |
| SCHEMBL3211797 | 0.82 | CPB2 (0.84) | CPB2 | |
| SCHEMBL3211197 | 0.82 | CPB2 (0.72) | CPB2 | |
| SCHEMBL27759893 | 0.82 | CPB2 (0.72) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | claimed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| EP-2104497-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | claimed |
| WO-2008067909-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | claimed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| WO-2008067909-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CPB2 61/4885MMP3 779/4885MMP1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.